Intangible Assets and Royalty Agreement (Details) (USD $)	3 Months Ended			9 Months Ended				9 Months Ended				0 Months Ended			9 Months Ended				9 Months Ended		9 Months Ended					9 Months Ended					9 Months Ended					9 Months Ended
	Sep. 30, 2014		Sep. 30, 2013	Sep. 30, 2014		Sep. 30, 2013	Dec. 31, 2013	Sep. 30, 2014 Licenses		Dec. 31, 2013 Licenses		Jan. 29, 2007 Licenses Shriners Hospitals for Children and University of South Florida Research Foundation, Inc.	Sep. 30, 2014 Licenses Shriners Hospitals for Children and University of South Florida Research Foundation, Inc.	Jan. 05, 2011 Licenses Surgical Biologics, LLC	Sep. 30, 2014 Patents & Know How		Dec. 31, 2013 Patents & Know How		Sep. 30, 2014 Patents & Know How Surgical Biologics, LLC	Jan. 05, 2011 Patents & Know How Surgical Biologics, LLC	Sep. 30, 2014 Customer & Supplier Relationships		Dec. 31, 2013 Customer & Supplier Relationships		Jan. 05, 2011 Customer & Supplier Relationships Surgical Biologics, LLC	Sep. 30, 2014 Tradenames & Trademarks		Dec. 31, 2013 Tradenames & Trademarks		Jan. 05, 2011 Tradenames & Trademarks Surgical Biologics, LLC	Sep. 30, 2014 In Process Research & Development		Dec. 31, 2013 In Process Research & Development		Jan. 05, 2011 In Process Research & Development Surgical Biologics, LLC	Sep. 30, 2014 Patents in Process		Dec. 31, 2013 Patents in Process
Finite-Lived Intangible Assets [Line Items]
Weighted Average Amortization Lives								10 years	[1],[2]						14 years	[1]					14 years	[1]
Gross Carrying Value								$ 1,009,000	[1],[2]	$ 1,009,000	[1],[2]			$ 13,000	$ 7,888,856	[1]	$ 7,798,910	[1]		$ 7,690,000	$ 3,761,000	[1]	$ 3,761,000	[1]	$ 3,761,000
Weighted Average Amortization Lives, Indefinite Lived																										indefinite	[1]				indefinite	[1]				indefinite	[3]
Gross Carrying Value, Indefinite Lived																										1,008,000	[1]	1,008,000	[1]	1,008,000	25,000	[1]	25,000	[1]	25,000	967,136	[3]	579,987	[3]
Total	14,658,992			14,658,992			14,181,897
Less Accumulated amortization	(3,698,692)			(3,698,692)			(3,003,324)
Net	10,960,300			10,960,300			11,178,573
Acquisition price												996,000
Maximum time of approval												30 days
Contingent payments to licensor													200,000
Contingent royalty to be paid to licensor (in hundredths)													3.00%
Annual royalty payment												50,000
Net book value	9,952,300			9,952,300									234,000
Finite-Lived Intangible Assets, Costs																			89,946
Amortization of intangible assets	232,079		259,575	695,368		789,809
Estimated future amortization expense [Abstract]
2014	232,306	[4]		232,306	[4]
2015	929,226			929,226
2016	929,226			929,226
2017	839,593			839,593
2018	829,626			829,626
Thereafter	6,192,323			6,192,323
Net book value	$ 9,952,300			$ 9,952,300									$ 234,000

[1] On January 5, 2011, the Company acquired Surgical Biologics, LLC. As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Trade Names & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. For the nine months ended September 30, 2014 an additional $89,946 of costs associated with patents granted during the period were capitalized and included in Patents & Know-How subject to amortization.

[2] On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000. Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor. Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license. As of September 30, 2014, this license had a remaining net book value of approximately $234,000

[3] Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.

[4] Estimated amortization expense for the year ending December 31, 2014, includes only amortization to be recorded after September 30, 2014.